Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $78.00

Halozyme Therapeutics (NASDAQ:HALO) had its price objective lifted by JPMorgan Chase & Co. from $70.00 to $78.00 in a research report released on Thursday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Citizens Jmp increased their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $83.00 to $110.00 in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Halozyme Therapeutics Stock Up 0.5%

Shares of NASDAQ:HALO opened at $110.42 on Thursday. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $116.85. The firm’s 50 day moving average price is $106.20 and its 200 day moving average price is $83.05. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a market cap of $12.53 billion, a price-to-earnings ratio of 32.96, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts predict that Halozyme Therapeutics will post 8.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock valued at $13,538,046 over the last quarter. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Horizon Investment Services LLC purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $2,254,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Halozyme Therapeutics during the second quarter worth about $1,025,000. Chase Investment Counsel Corp purchased a new position in shares of Halozyme Therapeutics during the second quarter worth about $2,035,000. Great Lakes Advisors LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at about $2,821,000. Finally, WINTON GROUP Ltd increased its position in Halozyme Therapeutics by 704.6% in the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after acquiring an additional 52,848 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: A Dutch court ordered Merck to stop manufacturing, selling, importing, or stocking subcutaneous Keytruda in eight European markets after finding that the product infringed a Halozyme patent. The ruling strengthens Halozyme’s intellectual-property position and could support future royalty economics, although appeals remain possible. Halozyme wins court order to block Merck’s injected Keytruda
• Positive Sentiment: Halozyme expanded its ENHANZE collaboration with argenx to include two additional exclusive targets, bringing the total to eight. The broader agreement increases potential milestone payments, royalties, and recurring licensing revenue. Halozyme expands Argenx deal
• Neutral Sentiment: Reported short interest was zero shares, implying no measurable short-selling pressure; however, the disclosure that short interest had increased appears inconsistent with the reported total and may reflect a data issue.
• Neutral Sentiment: CEO Helen Torley sold 20,000 shares for roughly $2.19 million under a pre-arranged Rule 10b5-1 trading plan. The sale reduced her holdings by 2.54%, but she still owns approximately 767,780 shares, making the transaction less significant as a bearish signal. Halozyme CEO Helen Torley sells shares
• Negative Sentiment: JPMorgan raised its price target from $70 to $78 but maintained a “neutral” rating. The target remains substantially below HALO’s recent trading level, suggesting the analyst believes the stock’s legal and growth prospects are already largely reflected in its valuation. JPMorgan raises Halozyme price target

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.